NIKKEI 225
39,341.54 -325.53 (-0.82%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
81.88 +0.14 (+0.17%) GOLD FUTURES
2,337.90 +1.30 (+0.06%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,678.60 +619.31 (+1.29%)
Koninklijke Philips N.V. (PHIAA.XC)
| Previous close | 24.36 |
| Open | 23.98 |
| Bid | 23.91 x 0 |
| Ask | 24.29 x 0 |
| Day's range | 23.92 - 24.06 |
| 52-week range | 16.17 - 25.97 |
| Volume | |
| Avg. volume | 659 |
| Market cap | 22.424B |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings date | 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 May 2023 |
| 1y target est | N/A |
BenzingaBillionaire Agnelli Is Philips' Largest Shareholder Now - What's Going On?
Royal Philips NV (NYSE:PHG) shares are trading higher on Wednesday. Italy's famous Agnelli family has increased its investment in Philips, showcasing a robust vote of confidence in the Dutch firm known for its medical devices. Through Exor NV, the family's holding company, the Agnellis now controls 17.51% of Philips, enhancing their position as the company's largest shareholder, an increase from 16.1% recorded in May. This expansion in their stake is indicative of growing trust in Philips' marke
ReutersPhilips shares climb 2.5% after top investor Exor boosts stake
AMSTERDAM (Reuters) -Philips shares rose more than 2.5% on Wednesday, a day after a U.S. Securities and Exchange Commission filing showed Exor, investment arm of Italy's Agnelli family, had increased its stake in the Dutch healthcare technology group. According to the filing on Tuesday, Exor now owns 17.51% of Philips, up from 15.1%, strengthening its position as top investor of the group. A spokesman for Netherlands-based Exor - which can further increase its stake in Philips to as much as 20% - declined to give details about the stake increase or any potential further share purchase.
- Yahoo Finance Video
Eli Lilly seeks to expand Zepbound use to treat sleep apnea
Eli Lilly (LLY) is reporting success in the use of Zepbound — one of the pharmaceutical giant's landmark GLP-1 weight-loss drugs — to treat sleep apnea. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Eli Lilly's filing for approval from the US Food and Drug Administration (FDA) for this use case and how it may affect makers of CPAP (Continuous Positive Airway Pressure) sleep devices, such as Philips (PHG) and ResMed (RMD). For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
